Clinical Trial Update: Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety/efficacy study of SGN-15 in combination with gemcitabine for ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• SGN-15

Snippet

Sponsor: Seagen Inc. | Conditions: Ovarian Neoplasms | Phase 2 | Status: TERMINATED